Ceftaroline fosamil demonstrated high clinical cure and microbiological response rates in hospitalized patients with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile similar to that of ceftriaxone and consistent with the cephalosporin class. In this study, ceftaroline fosamil was an effective and well-tolerated treatment option for CAP.
Introduction. Previous studies have shown that patients with obesity had left ventricular hypertrophy (LVH) in 27–69,4% cases along with normal geometry of left ventricle (LV).Aim. To investigate new possible clinical and hormonal predictors of LVH in women with obesity of different degrees.Materials and methods. We conducted trans-sectional study in women with obesity, we performed clinical examination and echocardiography with calculation of mass of myocardium of LV (MMLV), indexed MMLV (IMMLV) to body surface area and relative wall thickness (RWT). LVH was diagnosed at IMMLV≥95 g/m2, increase of RWT when RWT≥0.42. Blood levels of fasting insulin, leptin and adiponectin were investigated. Differences between groups were assessed with Student’s t-test for independent samples, U-criterion of Mann-Whitney and Chi-square test (χ2). Correlation was estimated with Spearman's coefficient (rs). Multiple and logistic regression analyses were performed for detection of predictors. Statistics were performed with SPSS (version 13.0), differences were significant at level p0.05.Results. We assessed the results in 113 women (age 44.34±11.18 years, body mass index 35.0±5.3 kg/m2). Total 67 women were diagnosed with LVH (59.3%), 56.5% among them had arterial hypertension (AH). Increase of RWT was revealed in 25 participants (22.1%), 80% of them had arterial hypertension (AH). Levels of fasting leptin, insulin and adiponectin did not differ in groups of women with or without LVH, with or without increase of RWT. In multiple regression age (β=1.67, p=0,005), body mass (BM) (β=2.63, p=0.004) and mean blood pressure (BP) (β=1.07, p=0.009) were independent predictors of MMLV increase; age (β=0.83, p=0.006) and mean BP (β=0.56 p=0.007) – predictors of IMMLV increase. In logistic regression age (odds ratio (OR)=1.058, p=0.036) and BM (OR=1.065, p=0.05) were independent predictors of LVH; presence of AH (OR=4.011, p=0.05) and level of adiponectin (OR=2.618, p=0.048) – predictors of RWT increase.Conclusions. Women with obesity with or without AH had LVH in 59.3% cases. Age and BM were independent positive predictors of LVH, presence of AH and adiponectin – independent positive predictors of increase of RWT of LV.
Altogether 360 patients (63.4 % of men) were examined with the aim to reveal the incidence of carbohydrate metabolism disorder and evaluate its influence on the course of myocardial infarction. Of the 292 patients without known diabetes mellitus (DM) type 2 — 31.8 % had prediabetes, and 11.0 % had newly diagnosed DM type 2. Patients with carbohydrate metabolism disorder more often had acute heart failure (AHF Killip II-IV) (40.6 % of patients with normal glycaemia, 55.9 % with prediabetes, 62.6 % and 64.7 % with newly diagnosed and known DM, р = 0.039), and more apparent chronic heart failure (NYHA III-IV) (in 4.2; 9.4; 16.0 and 24.6 % respectively, р < 0.001). Twenty four-hour mortality was higher in patients with known DM type 2 than those without DM (13.2 and 2.3 %, р = 0.008). Regression analysis revealed that impaired glucose metabolism was associated with AHF (Killip II—III (OR = 1.27; 95 % CI: 1.05—1,.54, р = 0.014), Killip IV (OR = 1.39; 95 % CI: 1.06—1.82, р = 0.016)); DM type 2 was associated with higher rate of in-hospital mortality (OR = 4.71; 95 % CI: 2.27—9.78, р < 0.001).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.